Somatic hypermutation profiles in stereotyped IGHV4-34 receptors from South American chronic lymphocytic leukemia patients.

Chronic lymphocytic leukemia (CLL) is the most common mature B-cell neoplasm in the West. IGHV4-34 is one of the most frequently used genes in CLL patients, which usually display an indolent outcome. In this study, we explored the mutational profile of CLL patients expressing IGHV4-34 within different stereotypes and their association with prognostic factors and clinical outcome. A multi-institutional cohort of unselected 1444 CLL patients was analyzed by RT-PCR and bidirectional sequencing. Cytogenetics and molecular cytogenetics analyses were also performed. We identified 144 (10%) IGHV4-34 expressing cases, 119 mutated (M), 44 of them with stereotyped B-cell receptors. Subset #4 was the most frequent (56.8% of cases) followed by subsets #16 (13.6%), #29 (6.8%), and #201 (2.3%), with different distribution among countries. Analysis of somatic hypermutation profile showed significant differences among stereotyped subsets for G28>D/E, P45>S, E55>Q, and S64>I changes (p < 0.01) and high frequency of disruption of the glycosylation motif in the VH CDR2 region. All stereotyped IGHV4-34 cases showed normal karyotypes. Deletion 13q14 as a sole alteration was present in 42.8% of stereotyped cases with a different distribution among subsets. A shorter time to first treatment was found in non-stereotyped vs. stereotyped M-IGHV4-34 patients (p = 0.034). Our results add new information supporting the importance of recurrent amino acid changes at particular positions, contributing to refine the molecular characterization of South American CLL patients.

Anestesia total intravenosa con remifentanilo vs fentanilo como base analgésica en cirugía torácica electiva / Intravenous total anesthesia with remifentanil and fentanyl as analgesic base in elective thoracic surgery

Introducción: Mantener una oxigenación adecuada durante la ventilación a un solo pulmón es el problema fundamental al que se enfrenta el anestesiólogo durante la cirugía torácica, es por ello que se mantiene una constante búsqueda del método anestésico ideal que ayude a lograr dicho objetivo. Objetivos: Evaluar los resultados de dos técnicas de anestesia total intravenosa con remifentanilo y fentanilo como base analgésica e identificar la aparición de complicaciones durante la intervención quirúrgica. Métodos: Se realizó un estudio causiexperimental prospectivo, en el Hospital Docente Clínico Quirúrgico Dr. Salvador Allende, entre enero 2013 a diciembre 2015 en 40 pacientes ASA II o III que requirieron procedimientos intratorácicos. Estos se dividieron en dos grupos. A (remifentanilo-propofol) y B (fentanilo-propofol). Se estudiaron variables hemodinámicas, de oxigenación durante la ventilación unipulmonar, el tiempo de recuperación anestésica (ventilación espontánea, apertura ocular, extubación) y la analgesia posoperatoria. Resultados: No existieron variaciones significativas en la hemodinamia, ni en la oxigenación de los enfermos con el empleo de ambas técnicas anestésicas; sin embargo, el despertar y recuperación posoperatoria a corto plazo fue mejor en el grupo A. La intensidad del dolor posoperatorio según la escala visual análoga fue menor en el grupo B. Conclusiones: Ambas técnicas son efectivas para procedimientos quirúrgicos torácicos. Con mínima interferencia en la hemodinámia y parámetros de oxigenación(AU)

Introduction: Maintaining adequate oxygenation during single-lung ventilation is a fundamental concern faced by the anesthesiologist during thoracic surgery; therefore, a constant search is maintained for the ideal anesthetic method that helps achieve this goal is maintained. Objectives: To evaluate the outcomes of two total intravenous anesthesia techniques with remifentanil and fentanyl as analgesic base and to identify the onset of complications during surgery. Methods: A prospective and quasi-experimental study was carried out at Dr. Salvador Allende Clinical-Surgical Hospital, between January 2013 and December, with 40 ASA II or III patients who required intrathoracic procedures. These were divided into two groups: A (remifentanil-propofol) and B (fentanyl-propofol). Hemodynamic variables and others of oxygenation during one-lung ventilation were studied, together with anesthetic recovery time (spontaneous ventilation, ocular opening, extubation) and postoperative analgesia. Results: There were no significant variations in the hemodynamics or oxygenation of patients with the use of both anesthetic techniques; however, awakening and short-term postoperative recovery was better in group A. Postoperative pain intensity, based on the analogue-visual scale, was lower in group B. Conclusion: Both techniques are effective for thoracic surgical procedures, with minimal effect in hemodynamics and oxygenation parameters(AU)

Factores predictivos de hipoxemia durante la ventilación unipulmonar en el Hospital Dr. Salvador Allende / Predictive factors for hypoxemia during one-lung ventilation at Dr. Salvador Allende hospital

Introducción: mantener una adecuada oxigenación durante la ventilación pulmonar unilateral es la mayor preocupación durante la cirugía torácica. Identificar de antemano que paciente es más susceptible de presentar alteraciones en la oxigenación arterial constituye una ventaja importante. Objetivos: determinar la incidencia de hipoxemia durante la ventilación unipulmonar, así como que variables pre e intraoperatorias para predecirla. Métodos: se realizó una investigación observacional, analítica, retrospectiva y de cohorte, en el hospital Dr. Salvador Allende. Se tomó como población de estudio todos aquellos pacientes que requirieron intervención quirúrgica mediante procedimientos intratorácicos en el período comprendido entre enero del 2007 a diciembre 2011. Resultados: la incidencia de hipoxemia durante la ventilación unipulmonar fue de 9,7 %. La talla menor de 160 cm y el lado operado (derecho) mostraron una relación estadísticamente significativa con la posibilidad de desarrollar hipoxemia durante la ventilación unipulmonar. Conclusiones: la hipoxemia durante la ventilación unipulmonar en este hospital constituye un problema vigente y aunque las variables que mostraron significación estadística son poco modificables al menos son un indicador de pacientes con más riesgo.

Introduction: maintaining adequate oxygenation during one-lung ventilation is the main concern in thoracic surgery. Prior identification of patients who may present arterial oxygenation alterations is an important advantage. Objectives: determine the incidence of hypoxemia during one-lung ventilation, as well as the pre- and intraoperative variables predicting it. Methods: an observational analytical retrospective cohort study was conducted at Dr. Salvador Allende hospital. The study population was all patients requiring intrathoracic surgery from January 2007 to December 2011. Results: incidence of hypoxemia during one-lung ventilation was 9.7%. Height under 160 cm and the side operated on (right) showed a statistically significant relationship to the possibility of developing hypoxemia during one-lung ventilation. Conclusions: hypoxemia during one-lung ventilation is a current problem at the study hospital. Although statistically significant variables are not very modifiable, at least they serve as indicators for patients at greater risk.

Factores predictivos de hipoxemia durante la ventilación unipulmonar en el Hospital Dr Salvador Allende / Predictive factors for hypoxemia during one-lung ventilation at Dr. Salvador Allende hospital

Introducción: mantener una adecuada oxigenación durante la ventilación pulmonar unilateral es la mayor preocupación durante la cirugía torácica. Identificar de antemano que paciente es más susceptible de presentar alteraciones en la oxigenación arterial constituye una ventaja importante.Objetivos: determinar la incidencia de hipoxemia durante la ventilación unipulmonar, así como que variables pre e intraoperatorias para predecirla. Métodos: se realizó una investigación observacional, analítica, retrospectiva y de cohorte, en el hospital Dr. Salvador Allende. Se tomó como población de estudio todos aquellos pacientes que requirieron intervención quirúrgica mediante procedimientos intratorácicos en el período comprendido entre enero del 2007 a diciembre 2011. Resultados: la incidencia de hipoxemia durante la ventilación unipulmonar fue de 9,7 por ciento. La talla menor de 160 cm y el lado operado (derecho) mostraron una relación estadísticamente significativa con la posibilidad de desarrollar hipoxemia durante la ventilación unipulmonar. Conclusiones: la hipoxemia durante la ventilación unipulmonar en este hospital constituye un problema vigente y aunque las variables que mostraron significación estadística son poco modificables al menos son un indicador de pacientes con más riesgo(AU)

Introduction: maintaining adequate oxygenation during one-lung ventilation is the main concern in thoracic surgery. Prior identification of patients who may present arterial oxygenation alterations is an important advantage. Objectives: determine the incidence of hypoxemia during one-lung ventilation, as well as the pre- and intraoperative variables predicting it. Methods: an observational analytical retrospective cohort study was conducted at Dr. Salvador Allende hospital. The study population was all patients requiring intrathoracic surgery from January 2007 to December 2011. Results: incidence of hypoxemia during one-lung ventilation was 9.7 percent. Height under 160 cm and the side operated on (right) showed a statistically significant relationship to the possibility of developing hypoxemia during one-lung ventilation. Conclusions: hypoxemia during one-lung ventilation is a current problem at the study hospital. Although statistically significant variables are not very modifiable, at least they serve as indicators for patients at greater risk(AU)

Macrophage depletion following liposomal-encapsulated clodronate (LIP-CLOD) injection enhances megakaryocytopoietic and thrombopoietic activities in mice.

Megakaryocytopoiesis is the cellular process by which stem cells progress through commitment, proliferation and differentiation, leading to the production of platelets. In the mouse, this process is accomplished within the bone marrow (BM) and spleen microenvironment and is carried out by regulatory molecules and accessory cells, including macrophages, fibroblasts and endothelial-like cells. Previously, we demonstrated that specific macrophage depletion, using liposomal-encapsulated clodronate (LIP-CLOD), induced a rapid recovery of the platelet count in a mouse model of immune thrombocytopenia. We now show that LIP-CLOD treatment also provoked enhancement of both megakaryocytopoiesis and thrombocytopoiesis. In fact, a dose-dependent increase in the number of BM and spleen megakaryocytes was detected after treatment and this pattern correlated inversely to the macrophage count detected in these organs. Furthermore, the mice treated with the higher dose of LIP-CLOD showed signs of enhanced thrombopoiesis as they had an increased frequency of reticulated platelets and an improvement in the total platelet count 2 d later. In addition, the in vitro cytokine-induced megakaryocytopoiesis in BM and spleen cell cultures was significantly augmented in the presence of LIP-CLOD. Taken together, these results suggest that BM and spleen microenvironmental macrophages could be involved in the regulation of megakaryocyte and platelet production.

Tratamiento de trombocitopenias inmunes en un modelo experimental / Treatment of immune thrombocytopenias in an experimental model

La púrpura trombocitopénica inmune (PTI) es un desorden hematológico caracterizado por un aumento del consumo de plaquetas. La destrucción plaquetaria es mediada por el sistema retículo-endotelial (SRE), en especial macrófagos hepáticos y esplénicos. Nosotros demostramos que la eliminación específica de estas células utilizando clodronato encapsulado en liposomas (lipclod) induce un aumento del recuento plaquetario. Además, encontramos que la trombocitopenia puede puede ser revertida por el lipclod sin comprometer totalmente la integridad del SRE al cabo de 18h de tratamiento. Los tiempos de sangría de los animales tratados fueron similares a los de los de los animales controles, sugiriendo que la hemostasia está bien controlada en estos animales. Estos datos indican que el uso de lip-clod merece ser considerado como una estrategia de tratamiento para aquellos trombocitopénicos donde se procura elevar rápidamente el recuento plaquetario.

Análisis de factores pronósticos en leucemia linfática crónica. Valor predictivo del inmunofenotipo, el CD23 soluble y la morfología / Predictive factors in chronic lymphocytic leukemia. Value of immunophenotype, SCD23 and morphology

En LLC se reconocen factores pronósticos útiles como la duplicación linfocitaria, el estadio clínico y el patrón de infiltración medular. Otros, como el porcentaje de células CD38+, están en estudio y requieren confirmación. El objetivo del presente trabajo fue evaluar si existe asociación entre morfología, inmunofenotipo linfocitario, CD23 soluble (SL) y sobrevida libre de eventos (SLE). Se evaluaron prospectivamente 36 pacientes sin tratamiento. Se determinaron: morfología típica, mixta y LLC-PL; inmunofenotipo linfocitario (score de Matutes); niveles plasmáticos de CD23 SL; estadio clínico, duplicación linfocitaria; ß2 microglobulina y alteraciones citogenéticas. Se consideró evento: progresión de enfermedad (necesidad de tratamiento, evolución a estadios avanzados, desarrollo de organomegalia voluminosa) y muerte por enfermedad. Mediana de seguimiento 24 meses. Resultados: estadio 0: 11/36, SLE 80 por ciento; I: 10/36 SLE 90 por ciento; II: 13/36: III y IV: 2/36. SLE >= II 37 por ciento. p= 0.023. Duplicación linfocitaria: <12m 7/31, >12m 24/31. SLE 28 por ciento vs 80 por ciento p<0.001. Citogenético: normal 13/28; anormal 15/28. SLE 92 por ciento vs 54 por ciento p=0.053. +12 positiva 7/30, negativa 23/30. SLE 65 por ciento vs 66 por ciento. ß2 microglobulina normal 9/35, elevada 26/35; SLE 100 por ciento vs 53 por ciento p=0.006. D23 SL < 350 Ul/ml 15/32, > 350 Ul/ml 17/32. SLE 92 por ciento vs 53 por ciento p=0.005. Inmunofenotipo: Score 5: 15/36, Score 4: 19/36, SLE 64 por ciento. Score 3: 2/36. p=0.516. Morfología típica 17/35, mixta 17/35. SLE 81 por ciento vs. 57 por ciento p=0.099. LLC-PL 1/35. El CD 23 SL resultó adecuado para predecir SLE, particularmente útil en estadios iniciales sin otros marcadores de actividad. La morfología y el fenotipo linfocitario, dos variables accesibles, no fueron útiles para el propósito del estudio.

Tratamiento de trombocitopenias inmunes en un modelo experimental / Treatment of immune thrombocytopenias in an experimental model

La púrpura trombocitopénica inmune (PTI) es un desorden hematológico caracterizado por un aumento del consumo de plaquetas. La destrucción plaquetaria es mediada por el sistema retículo-endotelial (SRE), en especial macrófagos hepáticos y esplénicos. Nosotros demostramos que la eliminación específica de estas células utilizando clodronato encapsulado en liposomas (lipclod) induce un aumento del recuento plaquetario. Además, encontramos que la trombocitopenia puede puede ser revertida por el lipclod sin comprometer totalmente la integridad del SRE al cabo de 18h de tratamiento. Los tiempos de sangría de los animales tratados fueron similares a los de los de los animales controles, sugiriendo que la hemostasia está bien controlada en estos animales. Estos datos indican que el uso de lip-clod merece ser considerado como una estrategia de tratamiento para aquellos trombocitopénicos donde se procura elevar rápidamente el recuento plaquetario. (AU)

Análisis de factores pronósticos en leucemia linfática crónica. Valor predictivo del inmunofenotipo, el CD23 soluble y la morfología / Predictive factors in chronic lymphocytic leukemia. Value of immunophenotype, SCD23 and morphology

En LLC se reconocen factores pronósticos útiles como la duplicación linfocitaria, el estadio clínico y el patrón de infiltración medular. Otros, como el porcentaje de células CD38+, están en estudio y requieren confirmación. El objetivo del presente trabajo fue evaluar si existe asociación entre morfología, inmunofenotipo linfocitario, CD23 soluble (SL) y sobrevida libre de eventos (SLE). Se evaluaron prospectivamente 36 pacientes sin tratamiento. Se determinaron: morfología típica, mixta y LLC-PL; inmunofenotipo linfocitario (score de Matutes); niveles plasmáticos de CD23 SL; estadio clínico, duplicación linfocitaria; ß2 microglobulina y alteraciones citogenéticas. Se consideró evento: progresión de enfermedad (necesidad de tratamiento, evolución a estadios avanzados, desarrollo de organomegalia voluminosa) y muerte por enfermedad. Mediana de seguimiento 24 meses. Resultados: estadio 0: 11/36, SLE 80 por ciento; I: 10/36 SLE 90 por ciento; II: 13/36: III y IV: 2/36. SLE >= II 37 por ciento. p= 0.023. Duplicación linfocitaria: <12m 7/31, >12m 24/31. SLE 28 por ciento vs 80 por ciento p<0.001. Citogenético: normal 13/28; anormal 15/28. SLE 92 por ciento vs 54 por ciento p=0.053. +12 positiva 7/30, negativa 23/30. SLE 65 por ciento vs 66 por ciento. ß2 microglobulina normal 9/35, elevada 26/35; SLE 100 por ciento vs 53 por ciento p=0.006. D23 SL < 350 Ul/ml 15/32, > 350 Ul/ml 17/32. SLE 92 por ciento vs 53 por ciento p=0.005. Inmunofenotipo: Score 5: 15/36, Score 4: 19/36, SLE 64 por ciento. Score 3: 2/36. p=0.516. Morfología típica 17/35, mixta 17/35. SLE 81 por ciento vs. 57 por ciento p=0.099. LLC-PL 1/35. El CD 23 SL resultó adecuado para predecir SLE, particularmente útil en estadios iniciales sin otros marcadores de actividad. La morfología y el fenotipo linfocitario, dos variables accesibles, no fueron útiles para el propósito del estudio. (AU)

[Evolution of chronic lymphocytic leukemia: predictive value of immunophenotype, soluble CD23 and morphology]. / Evolución de la leucemia linfática crónica. Valor predictivo del inmunofenotipo, el CD23 soluble y la morfología.

UNLABELLED: Some prognostic factors are useful in chronic lymphocytic leukemia (CLL): lymphocyte doubling time, clinical stage and bone marrow pattern infiltration, while others, such as the percentage of CD38+ cells, are under study and require confirmation. The objective of this study was to evaluate whether there is an association between morphology, lymphocyte immunophenotype, soluble CD23 (sCD23) and progression free survival (PFS). A total of 36 non-treated patients were enrolled. We analysed prospectively: morphology (typical, mixed and PL-CLL); immunophenotypic profile (Matutes score); sCD23 plasma levels; clinical stage; lymphocyte doubling time; beta 2 microglobulin and karyotype abnormalities. Disease progression (need of treatment, progression to advanced stages, development of bulky organomegaly) and death related to disease were considered as events. Md of follow-up 24 mo. RESULTS: Stage 0: 11/36, PFS 80%; I: 10/36 PFS 90%; II: 13/36; III and IV: 2/36. SLE > or = II PFS 37%. p = 0.023. Lymphocyte doubling time < 12mo. 7/31; > 12mo. 24/31. PFS 28% vs. 80% p < 0.001. Karyotype: normal 13/28, abnormal 15/28. PFS 92% vs. 54% p = 0.053. Trisomy 12: positive 7/30, negative 23/30, PFS 66% vs. 65%. beta 2 microglobulin: normal 9/35; high 26/35. PFS 100% vs. 53% p = 0.006. sCD23 < 350 Ul/ml: 15/32; > 350 Ul/ml: 17/32. PFS 92% vs. 53% p = 0.005. Immunophenotype: Score 5: 15/36, Score 4: 19/36, PFS 64%. Score 3: 2/36. p = 0.516. Morphology: typical 17/35, mixed 17/35, PFS 81% vs. 57%, p = 0.099. PL-CLL 1/35. CONCLUSIONS: sCD23 was suitable to predict PFS, specially useful for early stages without additional markers of active disease. Morphology (excluding PL-CLL) and immunophenotype, two common tools, were not useful for the study purpose.

Rapid recovery of platelet count following administration of liposome-encapsulated clodronate in a mouse model of immune thrombocytopenia.

Immune thrombocytopenic purpura (ITP) is a haematological disorder characterized by increased platelet consumption. The destruction of platelets is mediated by the reticulo-endothelial system (RES), particularly by splenic and hepatic macrophages. Previously, we demonstrated in a mouse model of thrombocytopenia that the depletion of these cells by liposome-encapsulated clodronate (LIP-CLOD) induces the recovery of the platelet count. We now report that LIP-CLOD is capable of reversing the thrombocytopenia with minimal effects on both, functional RES integrity and platelet functionality. Our data indicate that thrombocytopenic mice treated with low doses of LIP-CLOD/body weight increase the platelet count to haemostatically safe values within 18 h of treatment. The predictable bleeding time was significantly decreased in these mice, suggesting that the circulating platelets have enhanced haemostatic capacity. Platelet functionality measured through the ADP-induced fibrinogen-binding assay showed normal platelet activation after treatment. Regarding immunological competence, mice treated with LIP-CLOD showed similar antibody titres against sheep red blood cells. However, antibody-dependent cell-mediated cytotoxicity carried out by splenocytes was reduced. All these data demonstrate that LIP-CLOD deserves consideration as a potential therapeutic approach in thrombocytopenic states in which the rapid increase of platelet count is the primary goal.

Evolucion de la leucemia linfatica cronica: valor predictivo del inmunofenotipo, el CD23 soluble y la morfologia / Evolution of chronic lymphocytic leukemia: predictive value of immunophenotype, soluble CD23 and morphology

Some prognostic factors are useful in chronic lymphocytic leukemia (CLL): lymphocyte doubling time, clinical stage and bone marrow pattern infiltration, while others, such as the percentage of CD38+ cells, are under study and require confirmation. The objective of this study was to evaluate whether there is an association between morphology, lymphocyte immunophenotype, soluble CD23 (sCD23) and progression free survival (PFS). A total of 36 non-treated patients were enrolled. We analysed prospectively: morphology (typical, mixed and PL-CLL); immunophenotypic profile (Matutes score); sCD23 plasma levels; clinical stage; lymphocyte doubling time; beta 2 microglobulin and karyotype abnormalities. Disease progression (need of treatment, progression to advanced stages, development of bulky organomegaly) and death related to disease were considered as events. Md of follow-up 24 mo. RESULTS: Stage 0: 11/36, PFS 80%; I: 10/36 PFS 90%; II: 13/36; III and IV: 2/36. SLE > or = II PFS 37%. p = 0.023. Lymphocyte doubling time < 12mo. 7/31; > 12mo. 24/31. PFS 28% vs. 80% p < 0.001. Karyotype: normal 13/28, abnormal 15/28. PFS 92% vs. 54% p = 0.053. Trisomy 12: positive 7/30, negative 23/30, PFS 66% vs. 65%. beta 2 microglobulin: normal 9/35; high 26/35. PFS 100% vs. 53% p = 0.006. sCD23 < 350 Ul/ml: 15/32; > 350 Ul/ml: 17/32. PFS 92% vs. 53% p = 0.005. Immunophenotype: Score 5: 15/36, Score 4: 19/36, PFS 64%. Score 3: 2/36. p = 0.516. Morphology: typical 17/35, mixed 17/35, PFS 81% vs. 57%, p = 0.099. PL-CLL 1/35. CONCLUSIONS: sCD23 was suitable to predict PFS, specially useful for early stages without additional markers of active disease. Morphology (excluding PL-CLL) and immunophenotype, two common tools, were not useful for the study purpose

Evolucion de la leucemia linfatica cronica: valor predictivo del inmunofenotipo, el CD23 soluble y la morfologia / Evolution of chronic lymphocytic leukemia: predictive value of immunophenotype, soluble CD23 and morphology

Some prognostic factors are useful in chronic lymphocytic leukemia (CLL): lymphocyte doubling time, clinical stage and bone marrow pattern infiltration, while others, such as the percentage of CD38+ cells, are under study and require confirmation. The objective of this study was to evaluate whether there is an association between morphology, lymphocyte immunophenotype, soluble CD23 (sCD23) and progression free survival (PFS). A total of 36 non-treated patients were enrolled. We analysed prospectively: morphology (typical, mixed and PL-CLL); immunophenotypic profile (Matutes score); sCD23 plasma levels; clinical stage; lymphocyte doubling time; beta 2 microglobulin and karyotype abnormalities. Disease progression (need of treatment, progression to advanced stages, development of bulky organomegaly) and death related to disease were considered as events. Md of follow-up 24 mo. RESULTS: Stage 0: 11/36, PFS 80%; I: 10/36 PFS 90%; II: 13/36; III and IV: 2/36. SLE > or = II PFS 37%. p = 0.023. Lymphocyte doubling time < 12mo. 7/31; > 12mo. 24/31. PFS 28% vs. 80% p < 0.001. Karyotype: normal 13/28, abnormal 15/28. PFS 92% vs. 54% p = 0.053. Trisomy 12: positive 7/30, negative 23/30, PFS 66% vs. 65%. beta 2 microglobulin: normal 9/35; high 26/35. PFS 100% vs. 53% p = 0.006. sCD23 < 350 Ul/ml: 15/32; > 350 Ul/ml: 17/32. PFS 92% vs. 53% p = 0.005. Immunophenotype: Score 5: 15/36, Score 4: 19/36, PFS 64%. Score 3: 2/36. p = 0.516. Morphology: typical 17/35, mixed 17/35, PFS 81% vs. 57%, p = 0.099. PL-CLL 1/35. CONCLUSIONS: sCD23 was suitable to predict PFS, specially useful for early stages without additional markers of active disease. Morphology (excluding PL-CLL) and immunophenotype, two common tools, were not useful for the study purpose (AU)

Evolución de la leucemia linfática crónica. Valor predictivo del inmunofenotipo, el CD23 soluble y la morfología. / [Evolution of chronic lymphocytic leukemia: predictive value of immunophenotype, soluble CD23 and morphology]

Some prognostic factors are useful in chronic lymphocytic leukemia (CLL): lymphocyte doubling time, clinical stage and bone marrow pattern infiltration, while others, such as the percentage of CD38+ cells, are under study and require confirmation. The objective of this study was to evaluate whether there is an association between morphology, lymphocyte immunophenotype, soluble CD23 (sCD23) and progression free survival (PFS). A total of 36 non-treated patients were enrolled. We analysed prospectively: morphology (typical, mixed and PL-CLL); immunophenotypic profile (Matutes score); sCD23 plasma levels; clinical stage; lymphocyte doubling time; beta 2 microglobulin and karyotype abnormalities. Disease progression (need of treatment, progression to advanced stages, development of bulky organomegaly) and death related to disease were considered as events. Md of follow-up 24 mo. RESULTS: Stage 0: 11/36, PFS 80

; I: 10/36 PFS 90

; II: 13/36; III and IV: 2/36. SLE > or = II PFS 37

. p = 0.023. Lymphocyte doubling time < 12mo. 7/31; > 12mo. 24/31. PFS 28

vs. 80

p < 0.001. Karyotype: normal 13/28, abnormal 15/28. PFS 92

vs. 54

p = 0.053. Trisomy 12: positive 7/30, negative 23/30, PFS 66

vs. 65

. beta 2 microglobulin: normal 9/35; high 26/35. PFS 100

vs. 53

p = 0.006. sCD23 < 350 Ul/ml: 15/32; > 350 Ul/ml: 17/32. PFS 92

vs. 53

p = 0.005. Immunophenotype: Score 5: 15/36, Score 4: 19/36, PFS 64

. Score 3: 2/36. p = 0.516. Morphology: typical 17/35, mixed 17/35, PFS 81

vs. 57

, p = 0.099. PL-CLL 1/35. CONCLUSIONS: sCD23 was suitable to predict PFS, specially useful for early stages without additional markers of active disease. Morphology (excluding PL-CLL) and immunophenotype, two common tools, were not useful for the study purpose.

Proyecto industrial Catering hospitalario

Abarca toda una orientación técnica para el serviciode los distintos tipos de dietas, tenemos en cuenta que este ramo de la alimentación no puede cenir a una linea de producción industrial, nuestro Catering HHospitalario incluye lka implantación de una cocina metabólica que es un servicio alimentario elaborado por expertos nutricionistas, solo en un hospital cuenta actualmente con este servicio